Skip to content

Early detection of Hereditary Breast Cancer by Monitoring MicroRNA expression in Nipple Aspirate Fluid

Early detection of Hereditary Breast Cancer by Monitoring MicroRNA expression in Nipple Aspirate Fluid

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON24687
Enrollment
620
Registered
2020-05-25
Start date
2008-05-26
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer, hereditary breast cancer

Interventions

A onetime dose of 4 IE oxytocin nasal spray is administered prior to the nipple fluid aspiration (NFA) procedure. Nipple fluid is obtained through the use of a manual assisted vacuum-system. After sub

Sponsors

Vrienden UMC Utrecht
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - > 20% lifetime risk of developing breast cancer (e.g. due to germline mutations such as BRCA1 or BRCA2) - Previous DCIS/invasive breast cancer - Female = 18 years of all ethnic backgrounds

Exclusion criteria

Exclusion criteria: - Bilateral ablative breast surgery - Bilateral breast reduction with nipple graft - Pregnancy or lactation - Active breast infection - Disseminated breast cancer

Design outcomes

Primary

MeasureTime frame
- Predictive value of biomarkers in early breast cancer development, with a primary focus on miRNA. - To establish biomarker profiles in NAF, follow them in time and establish a correlation with breast cancer development. - To determine threshold values of these biomarkers that point to a significant risk of imminent breast cancer development thereby indicating the right time of prophylactic breast surgery.

Secondary

MeasureTime frame
Secondary Objectives: - To assess discomfort, uncertainty and distress experienced by subjects. - To set up a Biobank of blood samples and serum of women at increased breast cancer risk, providing opportunities to correlate molecular biomarker results in NAF to those in serum and/or plasma in the near future.

Contacts

Public ContactSusana Patuleia

UMC Utrecht

s.i.schoutenpatuleia-7@umcutrecht.nl088 75 691 50

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)